LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.050
+0.100 (+2.532%)
At close: 4:00PM EST

4.100 +0.05 (1.23%)
After hours: 4:01PM EST

Stock chart is not supported by your current browser
Previous Close3.950
Open3.900
Bid4.100 x 100
Ask4.250 x 1000
Day's Range3.900 - 4.100
52 Week Range2.300 - 6.496
Volume32,892
Avg. Volume41,385
Market Cap120.521M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.031
Earnings DateMar 14, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium    

    SAN DIEGO, Dec. 21, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, ...

  • GlobeNewswire2 months ago

    aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference

    SAN DIEGO, Dec. 07, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, ...

  • GlobeNewswire2 months ago

    aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

    –Second Physiocrine-based therapeutic candidate enters the clinic–. –Top-line data expected in 2 Q 2018–. –iMod.Fc to target interstitial lung diseases with an immune component–.

  • GlobeNewswire2 months ago

    aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference

    SAN DIEGO, Nov. 21, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, ...

  • Associated Press2 months ago

    Atyr Pharma reports 3Q loss

    The San Diego-based company said it had a loss of 43 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • GlobeNewswire2 months ago

    aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

    -Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter-. -Selection of antibody for ORCA program on-track for this quarter-. SAN DIEGO, Nov. 14, 2017-- aTyr Pharma, Inc., a biotherapeutics ...

  • GlobeNewswire3 months ago

    aTyr Pharma Announces Leadership Transition

    John Mendlein Transitions from CEO to Non-Executive Board Member, Dr. Sanjay Shukla Appointed President and CEO–. SAN DIEGO, Nov. 01, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the ...

  • Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
    Zacks3 months ago

    Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

    Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

  • How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?
    Simply Wall St.4 months ago

    How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?

    For aTyr Pharma Inc’s (NASDAQ:LIFE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measuresRead More...

  • Associated Press5 months ago

    Atyr Pharma reports 2Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 51 cents. In the final minutes of trading on Monday, the company's shares hit $3.25. A year ago, they were trading at $3.42. _____ ...

  • Associated Press8 months ago

    Atyr Pharma reports 1Q loss

    The San Diego-based company said it had a loss of 56 cents per share. In the final minutes of trading on Thursday, the company's shares hit $3.10. A year ago, they were trading at $3.01. _____ This story ...

  • PR Newswire10 months ago

    aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors

    SAN DIEGO, April 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Mr. Jeffrey S. Hatfield, as an independent board director, to aTyr Pharma's board of directors, effective immediately. Mr. Hatfield brings relevant industry operations experience and expertise to aTyr at an important and exciting time for aTyr's growth. Jeffrey S. Hatfield served as President, Chief Executive Officer of Vitae Pharmaceuticals from March 2004 through October 2016 when Vitae was acquired by Allergan, plc. During his tenure at Vitae, Mr. Hatfield focused the company on high value therapeutic areas with significant global unmet medical need, including autoimmune disorders, diabetes, immuno-oncology and more.